Literature DB >> 15528356

PIASy-deficient mice display modest defects in IFN and Wnt signaling.

Wera Roth1, Claudio Sustmann, Matthias Kieslinger, Andrea Gilmozzi, Denis Irmer, Elisabeth Kremmer, Chris Turck, Rudolf Grosschedl.   

Abstract

Protein inhibitors of activated STATs (PIAS) represent a small family of nuclear proteins that modulate the activity of many transcription factors and act as E3 ligases for covalent modification of proteins with the small ubiquitin-like modifier (SUMO). In particular, PIASy has been shown to inhibit the activation of gene expression by the IFN-responsive transcription factor STAT1 and the Wnt-responsive transcription factor LEF1. To assess the function of PIASy in vivo, we generated and analyzed mice carrying a targeted mutation of the Piasy gene. We find that homozygous mutant mice have no obvious morphological defects and have a normal distribution of lymphocyte populations. Molecular analysis of signaling in response to IFN-gamma and Wnt agonists revealed a modest reduction in the activation of endogenous and transfected target genes. Two-dimensional analysis of total proteins and SUMO-modified proteins in transformed pre-B cells showed no significant differences between wild-type mice and homozygous mutant mice. Taken together, our data indicate that PIASy has a modest effect on cytokine and Wnt signaling, suggesting a redundancy with other members of the family of PIAS proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528356     DOI: 10.4049/jimmunol.173.10.6189

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

Review 1.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

Review 2.  SUMO wrestling with type 1 diabetes.

Authors:  Manyu Li; Dehuang Guo; Carlos M Isales; Decio L Eizirik; Mark Atkinson; Jin-Xiong She; Cong-Yi Wang
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

3.  SUMO-1 modification of PIASy, an E3 ligase, is necessary for PIASy-dependent activation of Tcf-4.

Authors:  Motomasa Ihara; Hideki Yamamoto; Akira Kikuchi
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

4.  MafG sumoylation is required for active transcriptional repression.

Authors:  Hozumi Motohashi; Fumiki Katsuoka; Chika Miyoshi; Yasuhiro Uchimura; Hisato Saitoh; Claire Francastel; James Douglas Engel; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 5.  DNA topoisomerase II and its growing repertoire of biological functions.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

6.  Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression.

Authors:  Toru Kubota; Mayumi Matsuoka; Tsung-Hsien Chang; Prafullakumar Tailor; Tsuguo Sasaki; Masato Tashiro; Atsushi Kato; Keiko Ozato
Journal:  J Biol Chem       Date:  2008-07-17       Impact factor: 5.157

Review 7.  SUMO rules: regulatory concepts and their implication in neurologic functions.

Authors:  Mathias Droescher; Viduth K Chaugule; Andrea Pichler
Journal:  Neuromolecular Med       Date:  2013-08-30       Impact factor: 3.843

Review 8.  PIAS proteins: pleiotropic interactors associated with SUMO.

Authors:  Miia M Rytinki; Sanna Kaikkonen; Petri Pehkonen; Tiina Jääskeläinen; Jorma J Palvimo
Journal:  Cell Mol Life Sci       Date:  2009-06-13       Impact factor: 9.261

Review 9.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

10.  Spatial interplay between PIASy and FIP200 in the regulation of signal transduction and transcriptional activity.

Authors:  Nadine Martin; Klaus Schwamborn; Henning Urlaub; Boyi Gan; Jun-Lin Guan; Anne Dejean
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.